AY
Aytu BioPharma, Inc.
AYTU · NASDAQ
$2.05 +0.00% (+$0.00)
1M -3.30%
Market Cap $22.0M
P/E Ratio -
Div. Yield -
ROE 52.89%
Bulios Fair Price
$1.92
6.3% downside
Current Price
$2.05
Undervalued Fair Value Overvalued
According to Bulios Fair Price, AYTU is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
4/9Valuation
97 /100
Cheap P/S 0.38x
P/B 0.62x
P/FCF 13.38x
Growth
2 /100
Declining Rev. growth 18.77%
Book val. growth 3.59%
EPS growth N/A
Profitability
27 /100
Weak Gross margin 63.95%
Net margin 24.76%
Op. margin 14.44%
Quality
7 /100
Poor ROIC 15.93%
ROE 52.89%
ROA 13.57%
Debt
57 /100
Moderate Debt/Equity 0.05x
Current ratio 1.13x
Int. coverage -11.26x
Stability
51 /100
Moderate Beta 0.27x
Rev. volatility 20.81%
EPS volatility 12.00%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about AYTU
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Joshua R. Disbrow
Employees
76
Headquarters
Denver
Upcoming events
12 NOV
Earnings
Upcoming earnings report